share_log

Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie

Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie

Avalo Therapeutics | 4:持股變動聲明-高管 Doyle Mittie
美股sec公告 ·  07/16 16:27
Moomoo AI 已提取核心訊息
Chief Medical Officer of Avalo Therapeutics, Doyle Mittie, engaged in a transaction involving the company's stock on July 15, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and total value, were not disclosed in the announcement. Following the action, the updated number of shares held by Doyle Mittie in Avalo Therapeutics remains undisclosed.
Chief Medical Officer of Avalo Therapeutics, Doyle Mittie, engaged in a transaction involving the company's stock on July 15, 2024. The specific details of the transaction, including the number of shares, nature of shares, transaction price, and total value, were not disclosed in the announcement. Following the action, the updated number of shares held by Doyle Mittie in Avalo Therapeutics remains undisclosed.
2024年7月15日,Avalo Therapeutics的首席醫療官Doyle Mittie進行了一筆涉及該公司股票的交易。交易的具體細節,包括股份數量、股票性質、成交價格和總價值,在公告中未披露。在此次交易後,Doyle Mittie在Avalo Therapeutics持有的股份數量未公開。
2024年7月15日,Avalo Therapeutics的首席醫療官Doyle Mittie進行了一筆涉及該公司股票的交易。交易的具體細節,包括股份數量、股票性質、成交價格和總價值,在公告中未披露。在此次交易後,Doyle Mittie在Avalo Therapeutics持有的股份數量未公開。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息